Genome‐Wide Cell‐Free DNA Analysis for Aneuploidy Detection in Miscarriages: Test Performance Meta‐Analysis
Prenatal Diagnosis · 2025
DOI: 10.1002/pd.6824 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Prenatal Diagnosis, 2025. Verfasst von Montse Pauta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fetal Medicine Research Center, BCNatal. Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic de Barcelona and Hospital Sant Jo…. Hauptthemen laut MEDLINE: Aneuploidy, Abortion, Spontaneous, Cell-Free Nucleic Acids. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To conduct a systematic review and meta‐analysis of published series examining the efficacy of genome‐wide cell‐free DNA (cfDNA) testing in identifying aneuploidy in pregnancies ending in miscarriage.
Methods
A systematic review was conducted encompassing observational studies evaluating aneuploidy detection by genome‐wide cfDNA testing in pregnancy losses before 22 weeks of gestation. A hierarchical summary receiver operating curve was employed to assess pooled sensitivity, specificity, and area under the curve (AUC) of genome‐wide cfDNA versus genetic diagnostic studies in the detection of aneuploidy. Pooled aneuploidy rate, rate of no‐calls, and concordance between cfDNA and diagnostic studies were analyzed using a single proportion meta‐analysis based on the inverse of the variance.
Results
Out of 25 eligible series, eight studies were included for analysis, comprising 552 miscarriages with informative results for both cfDNA and diagnostic testing. Pooled sensitivity, specificity, and AUC were 78% (95% CI: 71%–83%), 91% (95% CI: 86%–95%), and 92%, respectively. Pooled aneuploidy rate, the proportion of no‐calls, and concordance were 61% (95% CI: 53%–69%), 4% (95% CI: 0%–12%), and 84% (95% CI: 81%–87%), respectively. In cases of positive cfDNA results, the risk of aneuploidy increased to 93%, whereas negative results yielded a 28% risk of aneuploidy. Conclusion cfDNA testing demonstrates acceptable accuracy in predicting fetal aneuploidy when employed as a screening test in miscarriages. The main advantage of cfDNA testing is that it does not require the availability of products of conception or prior chorionic villi sampling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fetal Medicine Research Center, BCNatal. Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic de Barcelona and Hospital Sant Joan de Deu), Barcelona, Spain.
- Hospital Clínic de Barcelona, Institut Clínic de Ginecologia, Obstetricia i Neonatologia, Barcelona, Spain.
- Iberoamerican Research Network in Translational, Molecular and Maternal-Fetal Medicine, Mexico City, Mexico.
- Instituto Nacional de Perinatología, Mexico City, Mexico.
- Center for Biomedical Research on Rare Diseases (CIBER-ER), Madrid, Spain.
ORCID-Profile: Montse Pauta, Raigam J Martinez-Portilla, Victoria Ardiles-Ruesjas
Zitieren
APA
Pauta, M., Martinez-Portilla, R. J., Jara-Ettinger, A. C., Ardiles-Ruesjas, V., & Borrell, A. (2025). Genome‐Wide Cell‐Free DNA Analysis for Aneuploidy Detection in Miscarriages: Test Performance Meta‐Analysis. Prenatal Diagnosis. https://doi.org/10.1002/pd.6824
Vancouver
Pauta M, Martinez-Portilla RJ, Jara-Ettinger AC, Ardiles-Ruesjas V, Borrell A. Genome‐Wide Cell‐Free DNA Analysis for Aneuploidy Detection in Miscarriages: Test Performance Meta‐Analysis. Prenatal Diagnosis. 2025. doi:10.1002/pd.6824
BibTeX
@article{Pauta2025,
author = {Pauta, Montse and Martinez-Portilla, Raigam J and Jara-Ettinger, Ana Cecilia and Ardiles-Ruesjas, Victoria and Borrell, Antoni},
title = {Genome‐Wide Cell‐Free DNA Analysis for Aneuploidy Detection in Miscarriages: Test Performance Meta‐Analysis},
journal = {Prenatal Diagnosis},
year = {2025},
doi = {10.1002/pd.6824}
}
EUVIMED